Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M

BIODESIX INC

FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.
Lung Diagnostic testing revenue $64.7M (+43% YoY); Biopharma Services $6.6M (+70% YoY).
Net loss $42.9M improved 18%; adjusted EBITDA loss $22.1M improved 32% vs FY2023.
Cash $26.2M at Dec 31, 2024; post-quarter amended term loan to extend $10M Tranche C availability.
FY2025 total revenue guidance $92-95M, representing 29-33% growth over FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.